多药联用致中毒性表皮坏死松解症1例分析

doi:10.19803/j.1672-8629.2022.02.24

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (2): 219-220.
DOI: 10.19803/j.1672-8629.2022.02.24

多药联用致中毒性表皮坏死松解症1例分析

刘雪姣, 岳慧杰, 吴燕子, 黄晓晖^*

东部战区总医院临床药学科,江苏南京 210016

收稿日期:2020-03-30 出版日期:2022-02-15 发布日期:2022-02-15
通讯作者: ^*黄晓晖,女,主管药师,临床药学。E-mail：9659510@qq.com
作者简介:刘雪姣,女,初级药师,临床药学。
基金资助:
江苏省自然科学基金青年基金项目资助（BK20180292）

Toxic epidermal necrolysis caused by multi-drug combinations: a case report

LIU Xuejiao, YUE Huijie, WU Yanzi, HUANG Xiaohui^*

Department of Clinical Pharmacy, Jinling Hospital, School of Medicine, Nanjing University, Nanjing Jiangsu 210016, China

Received:2020-03-30 Online:2022-02-15 Published:2022-02-15

摘要/Abstract

摘要： 目的探讨患者发生中毒性表皮坏死松解症的病因。方法梳理患者的诊疗经过,通过药物筛查、病原学检测和遗传学检测进行分析,探讨患者发生严重药品不良反应的原因。结果可疑药物包括头孢哌酮舒巴坦、洛哌丁胺、泮托拉唑,Narranjo评分无法区分可疑药物,ALDEN评分对3种可疑药物得的判断分别为“很可能”“可能”“可能”。基因检测显示患者未出现人类白细胞抗原等位基因突变;病原学检出细环病毒16型、细环病毒27型、人类疱疹病毒5型。结论患者可能在病毒感染与免疫力低下情况下因注射用头孢哌酮钠舒巴坦钠诱发了中毒性表皮坏死松解症。

关键词: Stevens-Johnson综合征, 中毒性表皮坏死松解症, 头孢哌酮舒巴坦, 人类白细胞抗原等位基因, 病毒, 药品不良反应

Abstract: Objective To investigate the etiology of toxic epidermal necrolysis. Methods The process of diagnosis and treatment of one case of toxic epidermal necrolysis was reviewed. The causes of serious drug adverse reactions were analyzed based on drug screening, pathogen detection and genetic detection. Results The drugs that might have caused toxic epidermal necrolysis included cefoperazone sulbactam sodium, loperamide and pantoprazole. The Narranjo score failed to distinguish suspicious drugs. The ALDEN score judged the three drugs as“probable”, “possible” and “possible”. Genetic test showed that the patient did not have any mutation of human leukocyte antigen alleles. The etiology of the patient's blood detected the fine ring virus type 16, type 27 and human herpes virus type 5, which might have increased the susceptibility to the disease. Conclusion The toxic epidermal necrolysis of this patient might have been caused by cefoperazone sulbactam sodium along with viral infection and low immunity.

Key words: Stevens-Johnson syndrome, toxic epidermal necrolysis, cefoperazone sulbactam, human leukocyte antigen allele, virus, adverse drug reaction

中图分类号:

R969.3R994.11

刘雪姣, 岳慧杰, 吴燕子, 黄晓晖. 多药联用致中毒性表皮坏死松解症1例分析[J]. 中国药物警戒, 2022, 19(2): 219-220.

LIU Xuejiao, YUE Huijie, WU Yanzi, HUANG Xiaohui. Toxic epidermal necrolysis caused by multi-drug combinations: a case report[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 219-220.

参考文献

[1] STERN RS, DIVITO SJ.Stevens-Johnson syndrome and toxic epidermal necrolysis: association, outcomes, and pathobiology-thirty years of progress but still much to be done[J]. J Invest Dermatol, 2017, 137(5): 1004-1008.
[2] SEKULA P, DUNANT A, MOCKENHAUPT M, et al.Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. J Invest Dermatol, 2013, 133(5): 1197-1204.
[3] SCHWARTZ RA, MCDONOUGH PH, LEE BW. Toxic epidermal necrolysis: part I. introduction, history, classification, clinical features, systemic manifestations, etiology,immunopathogenesis[J]. J Am Acad Dermatol, 2013, 69(2): 173.e1-13.
[4] SOTOZONO C, UETA M, NAKATANI E, et al.Predictive factors associ-ated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Am J Ophthalmol, 2015, 160(2): 228-237.
[5] SCHWARTZ RA, MCDONOUGH PH, LEE BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention,treatment[J]. J Am Acad Dermatol, 2013, 69(2): 187.e1-16.
[6] JANOUK D, SIMONE C, CHIARA G, et al.Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry[J]. Pharmacoepidemiol Drug Saf, 2015, 25(2): 196-203.
[7] MOCKENHAUPT M, VIBOUD C, DUNANT A, et al.Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. TheRuroSCAR-study[J]. J Invest Dermatol, 2008, 128(1): 35-44.
[8] GOLDMAN JL, CHUNG WH, LEE BR, et al.Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement[J]. Eur J Clin Pharmacol, 2019, 75(8): 1135-1141.
[9] SASSOLAS B, HADDAD C, MOCKENHAUPT M, et al.ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case control analysis[J]. Clin Pharmacol Ther, 2010, 88(1): 60-68.
[10] PEI Y, WANG R, WANG DD, et al.Literature analysis of HLA-B*5801 polymorphisms and cutaneous adverse reactions induced by allopurinol[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 154-156.
[11] LI X, YU K, MEI S, et al.HLA-B *1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies[J]. Drug Res (Stuttg), 2015, 65(2): 107-111.
[12] KHALAF D, TOEMA B, DABBOUR N, et al.Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis[J]. Mediterr J Hematol Infect Dis, 2011, 3(1): e2011004.
[13] LERCH M, MAINETTI C, TERZIROLI B, et al.Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Clin Rev Allergy Immunol, 2018, 54(1): 147-176.
[14] WU XF, LIN Z, LI Y, et al.Retrospective analysis of 346 cases of drug eruptions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 149-153.
[15] MA ZT, GONG R, FU NS, et al.Death due to serious toxic epidermal necrolysis evoked by cefoperazone sodium and sulbactam sodium[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2017, 19(2): 127-129.
[16] LEE HY, Tharmotharampillai T, Pang SM, et al.Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults[J]. Int J Dermatol, 2017, 56(4): e78-e79.
[17] AMSTUTZ U, SHEAR NH, RIEDER MJ, et al.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions[J]. Epilepsia, 2014, 55(4): 496-506.
[18] SAITO Y, STAMP LK, CAUDLE KE, et al.Clinical Pharmaco-genetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update[J]. Clin Pharmacol Ther, 2016, 99(1): 36-37.

多药联用致中毒性表皮坏死松解症1例分析

Toxic epidermal necrolysis caused by multi-drug combinations: a case report

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙绮悦, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 基于多动物模型药效评价体系研究羚羊感冒口服液儿童用药剂量[J]. 中国药物警戒, 2024, 21(2): 121-126.
[2]	孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131.
[3]	赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136.
[4]	包蕾, 耿子涵, 李舒冉, 冀祖恩, 赵荣华, 孙静, 郭姗姗, 崔晓兰. 瞬时受体电位通道在病毒性肺炎发展过程中的关键作用[J]. 中国药物警戒, 2024, 21(2): 137-140.
[5]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[6]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[7]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[8]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[9]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[10]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[11]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[12]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[13]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[14]	张宇, 张薇, 高双荣, 陈梦苹, 王雅欣, 徐英莉, 曹姗, 赵荣华, 包蕾, 李舒冉, 孙静, 鲍岩岩, 耿子涵, 郭姗姗, 冀祖恩, 崔晓兰. 基于蛋白质芯片技术筛选与甲型流感病毒NS1蛋白互作的宿主因子及通路分析[J]. 中国药物警戒, 2024, 21(1): 40-44.
[15]	曹姗, 庞博, 徐英莉, 张敬升, 陈梦苹, 张宇, 王雅欣, 包蕾, 耿子涵, 郭姗姗, 赵荣华, 崔晓兰. 疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响[J]. 中国药物警戒, 2024, 21(1): 45-50.